Compare GSM & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSM | FLGT |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Medical Specialities |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 964.9M | 525.3M |
| IPO Year | 2015 | 2016 |
| Metric | GSM | FLGT |
|---|---|---|
| Price | $4.50 | $16.44 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | $6.00 | ★ $28.33 |
| AVG Volume (30 Days) | ★ 1.2M | 584.1K |
| Earning Date | 05-06-2026 | 05-01-2026 |
| Dividend Yield | ★ 1.38% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $18,730,000.00 |
| Revenue This Year | $23.36 | $10.09 |
| Revenue Next Year | $17.85 | $12.18 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.04 | $13.46 |
| 52 Week High | $5.74 | $31.04 |
| Indicator | GSM | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 56.01 | 49.63 |
| Support Level | $4.31 | $15.39 |
| Resistance Level | $4.54 | $16.88 |
| Average True Range (ATR) | 0.19 | 0.72 |
| MACD | 0.07 | 0.23 |
| Stochastic Oscillator | 90.14 | 80.30 |
Ferroglobe PLC provides silicon-based alloys and specialty metals. It produces silicon metal and silicon and manganese-based alloy, serving customers in the specialty chemical, aluminum, solar, steel, and ductile iron foundry industries. The company's business segments include North America- Silicon, North America -Silicon Alloys; Europe Manganese; Europe Silicon Metals; Europe -Silicon Alloys, South Africa Silicon Metals, South Africa-Silicon Alloys, and Other segments The primary raw materials company uses to produce its electrometallurgy products includes its coal and quartz mining operations and its silicon metal and ferroalloy production.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.